https://www.ophthalmologytimes.com/view/six-cases-of-occlusive-retinal-vasculitis-linked-to-pegcetacoplan-injection-have-been-reported-by-asrs 2023-07-19 0.50 https://www.ophthalmologytimes.com/view/eye-drops-could-provide-a-more-effective-and-comfortable-therapy-for-retinal-vein-occlusion 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/celebrating-retina-care-the-2023-excellence-in-eye-care-resident-recognition-awards- 2023-07-18 0.50 https://www.ophthalmologytimes.com/view/opthea-s-opt-302-to-be-featured-in-oral-presentation-during-asrs-2023 2023-07-17 0.50 https://www.ophthalmologytimes.com/view/researchers-develop-machine-learning-model-that-uses-retinal-scans-to-identify-mild-cognitive-impairment 2023-07-17 0.50 https://www.ophthalmologytimes.com/view/tenpoint-therapeutics-receives-70-million-series-a-financing 2023-07-13 0.50 https://www.ophthalmologytimes.com/view/cognition-therapeutics-doses-first-patient-in-phase-2-magnify-study-for-geographic-atrophy-and-amd 2023-07-13 0.50 https://www.ophthalmologytimes.com/view/akari-therapeutics-completes-evaluation-of-long-acting-pas-nomacopan-candidates-and-plans-clinical-trials-for-the-treatment-of-geographic-atrophy 2023-07-13 0.50 https://www.ophthalmologytimes.com/view/astellas-announced-licensed-use-of-the-intravitreal-retinotropic-r100-vector-invented-by-4dmt 2023-07-12 0.50 https://www.ophthalmologytimes.com/view/key-takeaways-on-managing-neovascular-amd-and-dme 2023-08-02 0.50 https://www.ophthalmologytimes.com/view/managing-concurrent-neovascular-amd-and-geographic-atrophy-ga- 2023-08-02 0.50 https://www.ophthalmologytimes.com/view/iris-and-aeye-health-partner-to-bring-ai-technology-integrations-to-more-providers-and-simplify-diabetic-retinopathy-screenings 2023-07-13 0.50 https://www.ophthalmologytimes.com/view/apellis-pharmaceutical-to-share-data-during-oral-presentations-at-asrs-2023-in-seattle 2023-07-11 0.50 https://www.ophthalmologytimes.com/view/vantage-surgical-solutions-announces-acquisition-of-ophthalmic-surgical-solutions 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/hilco-vision-s-las-vegas-facility-receives-national-association-of-boards-of-pharmacy-nabp-drug-distributor-accreditation 2023-07-11 0.50 https://www.ophthalmologytimes.com/view/ocular-posterior-segment-complications-of-the-covid-19-vaccination 2023-07-13 0.50 https://www.ophthalmologytimes.com/view/new-drug-application-accepted-by-australia-s-therapeutic-goods-administration-for-arcatus-arvn001-in-the-treatment-of-uveitic-macular-edema 2023-07-11 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-getting-a-bird-s-eye-view-of-the-seattle-scene 2023-07-07 0.50 https://www.ophthalmologytimes.com/view/screening-for-diabetic-retinopathy-1-image-says-it-all 2023-07-11 0.50 https://www.ophthalmologytimes.com/view/asrs-2023-premier-meeting-for-retina-science-and-innovation 2023-07-07 0.50 https://www.ophthalmologytimes.com/view/researchers-assess-relationship-between-visual-functioning-and-mortality-in-patients-with-amd 2023-07-10 0.50 https://www.ophthalmologytimes.com/view/opthea-announces-the-resignation-of-chief-medical-officer-and-the-appointment-of-senior-medical-advisor 2023-07-10 0.50 https://www.ophthalmologytimes.com/view/severe-visual-loss-in-patients-with-neovascular-amd-treated-with-anti-vegf-therapy-related-to-central-macular-thickness 2023-07-10 0.50 https://www.ophthalmologytimes.com/view/alumis-begins-patient-dosing-in-optyk-1-phase-2-clinical-trial-for-the-treatment-of-uveitis 2023-07-06 0.50 https://www.ophthalmologytimes.com/view/belite-bio-submits-application-to-expand-phoenix-phase-3-clinical-trial-to-taiwan 2023-07-06 0.50 https://www.ophthalmologytimes.com/view/role-of-biosimilars-in-neovascular-amd-and-dme-treatment 2023-07-07 0.50 https://www.ophthalmologytimes.com/view/approaches-to-step-therapy-in-neovascular-amd-and-dme 2023-07-07 0.50 https://www.ophthalmologytimes.com/view/bayer-shares-2-year-topline-results-of-aflibercept-8-mg-for-the-treatment-of-diabetic-macular-edema-dme- 2023-07-06 0.50 https://www.ophthalmologytimes.com/view/non-invasive-approach-may-predict-retinopathy-of-prematurity-earlier 2023-07-05 0.50 https://www.ophthalmologytimes.com/view/fda-gives-clearance-of-ind-for-sk0106-skyline-therapeutics-aav-gene-therapy-candidate-for-namd 2023-07-06 0.50 https://www.ophthalmologytimes.com/view/new-study-finds-estimated-9-6-million-people-in-the-us-have-dr-and-1-84-million-people-have-vtdr 2023-07-05 0.50 https://www.ophthalmologytimes.com/view/eyecare-partners-launches-advanced-comprehensive-ophthalmology-fellowship-and-opens-applications 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/intergalactic-therapeutics-releases-positive-preclinical-data-from-ig-002-for-abca4-related-retinopathies 2023-06-29 0.50 https://www.ophthalmologytimes.com/view/efficacy-and-safety-results-of-the-zeta-1-phase-2-trial-in-diabetic-retinopathy-at-the-83rd-scientific-sessions-of-the-ada 2023-06-27 0.50 https://www.ophthalmologytimes.com/view/oculis-releases-list-of-retina-specialists-and-topics-for-r-d-retina-day-on-july-11-2023 2023-07-03 0.50 https://www.ophthalmologytimes.com/view/handheld-spectrally-encoded-coherence-tomography-and-reflectometry-improving-inclusive-diagnostics-with-multimodality-oct 2023-07-07 0.50 https://www.ophthalmologytimes.com/view/shedding-light-on-the-cause-of-retinal-inflammation-after-gene-therapy 2023-06-20 0.50 https://www.ophthalmologytimes.com/view/gene-therapy-in-neovascular-amd-and-dme 2023-06-30 0.50 https://www.ophthalmologytimes.com/view/new-therapies-to-supplement-anti-vegf-treatments-in-neovascular-amd-and-dme 2023-06-30 0.50 https://www.ophthalmologytimes.com/view/visgenx-shares-positive-data-from-vgx-0111-gene-therapy-study-in-non-human-primates 2023-06-27 0.50 https://www.ophthalmologytimes.com/view/novel-therapies-in-neovascular-amd-and-dme-achieving-superior-anatomic-outcomes-with-fewer-injections 2023-06-29 0.50 https://www.ophthalmologytimes.com/view/study-shows-machine-learning-ability-to-identify-diabetic-retinopathy-progression 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyenuk-receives-clearance-for-detecting-diabetic-retinopathy-with-the-eyeart-ai-system 2023-06-28 0.50 https://www.ophthalmologytimes.com/view/study-finds-significant-variance-across-imaging-modalities 2023-06-26 0.50 https://www.ophthalmologytimes.com/view/retina-imaging-may-provide-key-insights-to-predict-cerebrovascular-diseases 2023-06-26 0.50 https://www.ophthalmologytimes.com/view/fda-issues-crl-for-aflibercept-8-mg-from-regeneron-pharmaceuticals 2023-06-27 0.50 https://www.ophthalmologytimes.com/view/retinalgenix-technologies-shares-preview-of-study-and-goals-for-establishing-universal-biomarkers-for-amd-treatment 2023-06-26 0.50 https://www.ophthalmologytimes.com/view/20-20-onsite-earned-site-readiness-certification-providing-mobile-option-for-clinical-trials 2023-06-26 0.50 https://www.ophthalmologytimes.com/view/dovetail-study-anti-il-6-monoclonal-antibody-is-effective-in-treating-uveitic-macular-edema 2023-06-20 0.50 https://www.ophthalmologytimes.com/view/emerging-therapies-in-neovascular-amd-and-dme 2023-06-23 0.50 https://www.ophthalmologytimes.com/view/faricimab-loading-dose-adherence-in-dme-therapy 2023-06-23 0.50 https://www.ophthalmologytimes.com/view/training-and-practice-are-key-to-learning-retinal-injection-techniques 2023-06-23 0.50 https://www.ophthalmologytimes.com/view/patient-cases-demonstrating-the-application-of-treat-and-extend-algorithm-for-faricimab-in-dme 2023-06-22 0.50 https://www.ophthalmologytimes.com/view/design-for-phase-2b-aspire-study-of-ubx1325-for-dme-announced-by-unity 2023-06-22 0.50 https://www.ophthalmologytimes.com/view/visual-and-anatomic-outcomes-with-faricimab-in-dme-using-the-treat-and-extend-algorithm 2023-06-22 0.50 https://www.ophthalmologytimes.com/view/ai-could-increase-health-equity-and-boost-adherence-to-annual-eye-examinations-in-patients-with-diabetes 2023-06-20 0.50 https://www.ophthalmologytimes.com/view/ai-advancements-in-ophthalmology-what-s-new-in-2023-so-far 2023-06-21 0.50 https://www.ophthalmologytimes.com/view/new-vegf-trap-for-wet-amd-takes-aim-at-vegf-c-and-vegf-d 2023-06-19 0.50 https://www.ophthalmologytimes.com/view/is-complement-therapy-the-path-forward-for-geographic-atrophy- 2023-06-26 0.50 https://www.ophthalmologytimes.com/view/experts-detail-innovative-therapies-for-dme-and-neovascular-amd 2023-06-19 0.50 https://www.ophthalmologytimes.com/view/soe-2023-antimicrobial-resistance-the-growing-challenge-and-new-innovations 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/ai-in-eye-care-in-japan-facing-the-emerging-challenges 2023-06-14 0.50 https://www.ophthalmologytimes.com/view/eyebio-does-first-participants-for-phase-1b-2-amarone-clinical-trial-for-dme-and-namd 2023-06-20 0.50 https://www.ophthalmologytimes.com/view/use-of-intraocular-steroids-in-dme 2023-06-16 0.50 https://www.ophthalmologytimes.com/view/the-yosemite-and-rhine-trials-in-dme 2023-06-16 0.50 https://www.ophthalmologytimes.com/view/soe-2023-current-treatment-options-for-diabetic-macular-edema 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/soe-2023-cataract-surgery-in-the-opaque-cornea-challenging-but-worthwhile 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/publication-of-review-article-highlights-potential-of-dazdotufide-as-potential-treatment-dr-amd-and-dme 2023-06-15 0.50 https://www.ophthalmologytimes.com/view/soe-2023-optic-neuropathy-versus-maculopathy 2023-06-15 0.50 https://www.ophthalmologytimes.com/view/south-korea-s-mfds-approved-initiation-of-phase-3-tinlarebant-clinical-trial-for-stargardt-disease 2023-06-15 0.50 https://www.ophthalmologytimes.com/view/soe-2023-a-mixed-method-study-of-geographic-atrophy 2023-06-15 0.50 https://www.ophthalmologytimes.com/view/soe-2023-development-of-maculopathy-after-excessive-caffeine-and-alcohol-intake 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/soe-2023-new-dehydrated-human-amniotic-membrane-promotes-healing-of-the-ocular-surface 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-announces-u-s-launch-of-preservision-areds-2-formula-soft-gels-plus-coq10 2023-06-16 0.50 https://www.ophthalmologytimes.com/view/12-month-data-for-otx-tki-shows-positive-results-for-treatment-of-wet-amd 2023-06-13 0.50 https://www.ophthalmologytimes.com/view/kalahari-phase-2-part-b-trial-has-completed-randomization-for-participants-with-dme 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-to-develop-new-gene-therapies-for-retinal-diseases-with-120-million-in-new-funding 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/behold-trial-ubx1325-a-potential-new-therapeutic-option-for-treating-diabetic-macular-edema 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/real-world-experience-with-intravitreal-dexamethasone-for-dme 2023-06-05 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-at-the-summit-2023-choosing-right-metrics-and-avoiding-bias-in-clinical-trials-to-prevent-waste 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-at-the-summit-2023-long-term-outcomes-with-pds-for-wet-amd 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-at-the-summit-2023-is-glycoimmunology-the-next-generation-treatment-paradigm-for-ga- 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-at-the-summit-2023-update-on-visual-function-data-from-derby-and-oaks-studies 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-summit-2023-avancincaptad-pegol-ga 2023-06-12 0.50 https://www.ophthalmologytimes.com/view/key-outcomes-of-trials-of-faricimab-in-dme 2023-06-09 0.50 https://www.ophthalmologytimes.com/view/challenges-in-dme-management 2023-06-09 0.50 https://www.ophthalmologytimes.com/view/the-significance-of-imaging-and-treatment-in-lattice-retinal-degeneration 2023-06-09 0.50 https://www.ophthalmologytimes.com/view/companies-join-forces-to-form-bns-opthalmics-with-pipeline-for-amd-treatment 2023-06-09 0.50 https://www.ophthalmologytimes.com/view/phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-diabetic-retinopathy-completes-enrollment 2023-06-08 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-to-present-12-month-top-line-data-from-phase-1-otx-tki-trial-for-wet-amd-at-the-2023-clinical-trials-at-the-summit-annual-meeting 2023-06-06 0.50 https://www.ophthalmologytimes.com/view/enrollment-complete-for-eyepoint-s-phase-2-pavia-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy 2023-06-05 0.50 https://www.ophthalmologytimes.com/view/alkeus-announces-150-million-series-b-financing-to-support-gildeuretinol-alk-001-and-the-appointment-of-joshua-boger-to-executive-chairman 2023-06-05 0.50 https://www.ophthalmologytimes.com/view/iris-completes-1-million-diabetic-retinal-exams 2023-06-02 0.50 https://www.ophthalmologytimes.com/view/first-patient-receives-dosing-with-avd-104-in-the-phase-2-siglec-trial-for-the-treatment-of-geographic-atrophy 2023-06-02 0.50 https://www.ophthalmologytimes.com/view/biomarkers-of-disease-at-baseline-in-neovascular-amd 2023-06-02 0.50 https://www.ophthalmologytimes.com/view/loading-dose-recommendations-of-faricimab-in-neovascular-amd 2023-06-02 0.50 https://www.ophthalmologytimes.com/view/enrollment-has-opened-for-clearside-biomedical-s-phase-2b-clinical-trial-of-cls-ax 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/european-society-of-ophthalmology-2023-explore-vision-in-the-heart-of-europe 2023-05-24 0.50 https://www.ophthalmologytimes.com/view/the-european-society-of-ophthalmology-s-soe-focus-on-young-ophthalmologists 2023-06-02 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-day-on-june-1-marks-the-organization-s-115th-year 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/nacuity-reaches-target-enrollment-for-npi-001-tablet-phase-1-2-clinical-trial-for-retinitis-pigmentosa- 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/icare-home-tonometers-optimize-patient-care 2023-05-26 0.50 https://www.ophthalmologytimes.com/view/coave-shares-positive-12-month-results-from-phase-i-ii-trial-of-ctx-pde6b-for-retinitis-pigmentosa 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/optos-announces-new-ultra-widefield-color-modality-for-increased-retinal-visualization 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/the-world-health-organization-celebrates-world-no-tobacco-day-on-may-31-2023 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/roche-canada-completes-negotiations-with-the-pcpa-for-vabysmo-to-treat-namd-and-dme 2023-05-30 0.50 https://www.ophthalmologytimes.com/view/researchers-find-experimental-drug-may-prevent-or-slow-vision-loss-in-people-with-diabetes 2023-05-30 0.50 https://www.ophthalmologytimes.com/view/oxurion-nv-enrolls-108-patients-in-kalahari-phase-2-part-b-clinical-trial-for-diabetic-macular-edema 2023-05-30 0.50 https://www.ophthalmologytimes.com/view/recruitment-completed-for-alimera-s-new-day-study 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/patent-filed-by-curative-biotechnology-with-international-consideration 2023-06-01 0.50 https://www.ophthalmologytimes.com/view/avixgen-releases-pipeline-updates-for-new-drugs 2023-05-25 0.50 https://www.ophthalmologytimes.com/view/safety-of-faricimab-in-neovascular-amd 2023-05-26 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-faricimab-treatment-in-neovascular-amd 2023-05-26 0.50 https://www.ophthalmologytimes.com/view/annexon-announces-topline-results-from-archer-phase-2-trial-of-anx007-for-geographic-atrophy-ga- 2023-05-26 0.50 https://www.ophthalmologytimes.com/view/ag-73305-phase-2a-trial-for-the-treatment-of-diabetic-macular-edema-dme-shows-promising-preliminary-safety-and-efficacy-data 2023-05-24 0.50 https://www.ophthalmologytimes.com/view/ihealthscreen-inc-applies-for-fda-510k-submission-for-ipredict-an-ai-based-software-as-a-medical-device-tool-to-diagnosis-amd 2023-05-24 0.50 https://www.ophthalmologytimes.com/view/the-korean-mfds-grants-ind-approval-for-pharmabcine-s-phase-i-clinical-trial-of-its-novel-tie2-agonistic-antibody-in-namd 2023-05-24 0.50 https://www.ophthalmologytimes.com/view/research-provides-evidence-for-protein-deletion-in-age-and-diabetes-related-retinal-diseases 2023-05-23 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-shares-nonclinical-data-to-support-ixo-vec-s-phase-2-clinical-development 2023-05-23 0.50 https://www.ophthalmologytimes.com/view/phase-2-study-of-abvc-biopharma-vitargus-receives-ethical-approval-at-sydney-eye-hospital-in-australia 2023-05-23 0.50 https://www.ophthalmologytimes.com/view/aiviva-biopharma-inc-begins-phase-1-trial-for-ai007-for-the-treatment-of-wet-amd-and-dme 2023-05-23 0.50 https://www.ophthalmologytimes.com/view/ophthalmologists-on-front-lines-of-identifying-victims-of-intimate-partner-violence-through-ocular-trauma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oculis-reveals-positive-top-line-results-for-ocs-01-eye-drops-to-treat-dme-during-stage-1-of-its-phase-3-diamond-trial 2023-05-22 0.50 https://www.ophthalmologytimes.com/view/use-of-faricimab-in-neovascular-amd-in-clinical-practice 2023-05-19 0.50 https://www.ophthalmologytimes.com/view/phase-3-studies-of-faricimab-in-neovascular-amd 2023-05-19 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-presents-gene-therapy-data-and-introduces-an-intravitreal-gene-therapy-program-for-geographic-atrophy 2023-05-19 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-sells-yutiq-to-alimera-sciences-inc-for-82-5-million-usd-plus-royalties 2023-05-18 0.50 https://www.ophthalmologytimes.com/view/ray-therapeutics-closes-series-a-financing-to-advance-therapeutics-in-clinical-development 2023-05-17 0.50 https://www.ophthalmologytimes.com/view/research-shows-drug-could-prevent-vision-loss-in-premature-newborns 2023-05-17 0.50 https://www.ophthalmologytimes.com/view/aviceda-therapeutics-appoints-patrick-johnson-to-its-board-of-directors 2023-05-17 0.50 https://www.ophthalmologytimes.com/view/ai-based-eye-disease-detection-startup-eyetelligence-raises-12-million-usd-from-investors 2023-05-23 0.50 https://www.ophthalmologytimes.com/view/study-shows-non-random-association-between-missing-electronic-health-record-data-regarding-the-severity-of-diabetic-retinopathy 2023-05-12 0.50 https://www.ophthalmologytimes.com/view/insights-for-early-detection-of-age-related-macular-degeneration 2023-05-11 0.50 https://www.ophthalmologytimes.com/view/fda-clears-c-light-to-market-retinal-eye-movement-monitor-retitrack- 2023-05-12 0.50 https://www.ophthalmologytimes.com/view/key-takeaways-from-advances-in-geographic-atrophy-presentation-at-the-17th-annual-controversies-in-modern-eye-care-symposium 2023-05-12 0.50 https://www.ophthalmologytimes.com/view/treatment-goals-in-neovascular-amd 2023-05-12 0.50 https://www.ophthalmologytimes.com/view/anti-vascular-endothelial-growth-factor-anti-vegf-therapies-in-neovascular-amd-and-dme 2023-05-12 0.50 https://www.ophthalmologytimes.com/view/espansione-group-announces-second-major-research-effort-for-photobiomodulation-pbm-technology- 2023-05-11 0.50 https://www.ophthalmologytimes.com/view/genetech-seeks-indication-for-faricimab-svoa-from-the-fda-for-retinal-vein-inclusion-rvo- 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/stress-resilience-enhancing-drugs-may-provide-new-therapeutics-to-treat-amd-dr-and-rp 2023-05-11 0.50 https://www.ophthalmologytimes.com/view/new-york-ophthalmologist-begins-syfovre-treatment-for-geographic-atrophy-in-patients-with-dry-amd 2023-05-11 0.50 https://www.ophthalmologytimes.com/view/inherited-retinal-disease-genetic-testing-week-begins-may-15 2023-05-11 0.50 https://www.ophthalmologytimes.com/view/laser-retinopexy-during-primary-scleral-buckling 2023-05-10 0.50 https://www.ophthalmologytimes.com/view/the-nod-audit-provides-data-and-insights-for-the-management-for-neovascular-age-related-macular-degeneration 2023-05-05 0.50 https://www.ophthalmologytimes.com/view/analysis-of-human-eye-tissue-from-unique-biorepository-may-lead-to-development-of-therapeutics-for-amd 2023-05-05 0.50 https://www.ophthalmologytimes.com/view/abu-dhabi-health-services-company-launches-clinic-to-address-uveitis-in-children 2023-05-05 0.50 https://www.ophthalmologytimes.com/view/new-research-identifies-genes-related-to-oxidative-stress-and-amd 2023-05-05 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-yosemite-and-rhine-trials-compare-faricimab-to-aflibercept 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/endogena-therapeutics-completes-enrollment-early-for-its-phase-1-2a-trial-of-ea-2353-for-retinitis-pigmentosa 2023-05-04 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-michael-ip-shares-5-year-follow-up-of-the-original-score2-dataset 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-geographic-atrophy-progression-in-the-phase-3-oaks-and-derby-trials 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-treatment-research-for-gucy2d-associated-leber-congenital-amaurosis-type-1 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-apellis-presents-research-on-visual-function-imaging-and-ai 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-the-value-of-holographic-optical-coherence-tomography-oct-and-continued-imaging-research 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-insights-at-the-annual-meeting-regarding-non-viral-gene-therapy-targeting-abca4-retinopathies 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/fda-clears-atsena-therapeutics-ind-application-for-a-phase-i-ii-clinical-trial-of-atsn-201 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-kiora-pharmaceuticals-presented-preliminary-results-for-kio-301 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/astellas-pharma-acquires-iveric-bio-for-a-reported-5-9-billion 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-clearside-biomedical-presents-data-on-suprachoroidal-injection-delivery-platform 2023-04-29 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-eyenuk-ceo-and-founder-kaushal-solanki-shares-eu-update-on-eyeart 2023-04-29 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-research-on-epigenetic-reprogramming-to-reverse-aging-and-restore-function-to-rgcs 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-lineage-cell-therapeutics-presents-results-of-rg6501-phase-1-2a-clinical-trial-for-treatment-of-ga-progression 2023-05-02 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-nanoscope-therapeutics-presents-data-on-mco-010-an-optogenetic-therapy-for-vision-restoration-in-advanced-retinitis-pigmentosaretina-pigmentosa 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-using-retinal-imaging-for-early-detection-of-diabetic-retinopathy-in-underserved-communities 2023-04-28 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-ascidian-therapeutics-shares-insight-on-new-gene-therapy 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-preclinical-data-for-ashvattha-therapeutics-anti-vegf-nanomedicine-d-4517-2-shared-at-annual-meeting 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-phase-2-ongoing-study-of-lbs-008-data-shared-for-treatment-of-adolescent-stargardt-disease 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-data-suggest-greater-retinal-drying-via-faricimab-when-compared-to-aflibercept-in-wet-amd-dme 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-announces-results-from-phase-2-behold-study-of-patients-with-dme 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-valitor-s-presentation-at-arvo-2023-details-preclinical-data-on-its-anti-vegf-biologic-in-development-for-durable-treatment-of-wet-amd 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/stoke-therapeutics-receives-authorization-to-initiate-a-phase-1-2-study-of-stk-002-for-adoa-in-the-uk 2023-04-26 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-atsena-therapeutics-shares-latest-safety-and-efficacy-data-on-possible-gene-therapy-for-gucy2d-associated-leber-congenital-amaurosis-lca1- 2023-04-27 0.50 https://www.ophthalmologytimes.com/view/photobiomodulation-promising-future-for-treating-drusenoid-pigment-epithelial-detachments-in-dry-amd 2023-04-26 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-carl-danzig-md-fasrs-shares-new-data-on-vision-loss-from-the-gather-clinical-program 2023-04-25 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-t-y-alvin-liu-md-discusses-predictive-ai-and-its-application-in-ophthalmology 2023-04-25 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-using-donor-tissue-to-identify-the-mechanism-cell-death-of-the-rpe 2023-04-25 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-eyevensys-reports-data-on-eys809-as-treatment-of-wet-amd 2023-04-25 0.50 https://www.ophthalmologytimes.com/view/luxa-biotechnology-shares-progress-of-phase-1-2a-clinical-trial-for-amd-treatment 2023-04-25 0.50 https://www.ophthalmologytimes.com/view/association-between-visual-impairment-and-neuropsychiatric-symptoms-of-dementia 2023-04-20 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-optical-coherence-tomography-and-the-assessment-of-cognitive-impairment-in-alzheimer-s-disease-and-related-dementias 2023-04-20 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-apellis-pharmaceuticals-presented-phase-3-data-analyses-of-pegcetacoplan-injection-for-ga 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-nonclinical-data-by-adverum-biotechnologies-regarding-potential-treatment-of-wet-amd 2023-04-24 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-ocular-blood-flow-and-its-relationship-to-acute-coronary-syndrome 2023-04-24 0.50 https://www.ophthalmologytimes.com/view/hydrogen-water-intake-improved-rbf-dysregulation-in-response-to-flicker-stimulation-and-systemic-hyperoxia-in-type-2-diabetic-mice 2023-04-24 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-retinal-engineering-and-rgc-replacement 2023-04-20 0.50 https://www.ophthalmologytimes.com/view/sb15-biosimilar-to-aflibercept-similar-in-efficacy-pharmacokinetics-safety-immunogenicity-at-56-weeks 2023-04-19 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-using-machine-learning-to-identify-visual-field-loss-in-optic-neuritis 2023-04-24 0.50 https://www.ophthalmologytimes.com/view/signature-features-of-early-retinal-ganglion-cell-damage-in-glaucoma 2023-04-19 0.50 https://www.ophthalmologytimes.com/view/multiomics-eye-study-identifies-genes-with-age-related-macular-degeneration-risks 2023-04-21 0.50 https://www.ophthalmologytimes.com/view/retinai-and-boehringer-ingelheim-partner-to-further-ai-identification-and-treatment-of-geographic-atrophy 2023-04-21 0.50 https://www.ophthalmologytimes.com/view/new-published-data-demonstrates-the-effects-of-pl8331-in-mouse-models-of-retinal-disease 2023-04-19 0.50 https://www.ophthalmologytimes.com/view/new-deep-learning-network-may-improve-diagnosis-of-diabetic-retinopathy 2023-06-07 0.50 https://www.ophthalmologytimes.com/view/plans-for-phase-2b-clinical-trial-of-cls-ax-for-treatment-of-wet-amd-announced 2023-04-19 0.50 https://www.ophthalmologytimes.com/view/two-faricimab-patient-cases-from-the-real-world-in-neovascular-amd 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/study-design-and-preliminary-results-from-the-truckee-study-evaluating-faricimab-in-real-world-neovascular-amd-patients 2023-05-01 0.50 https://www.ophthalmologytimes.com/view/complement-therapeutics-completes-series-a-funding-with-72-million-a-step-toward-new-therapies-for-ga-and-dry-amd 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/visual-acuity-outcomes-after-repair-of-uncomplicated-rhegmatogenous-retinal-detachments 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/aviceda-announces-fda-clearance-of-the-ind-application-for-avd-104-enabling-initiation-of-phase-2-clinical-trials 2023-04-17 0.50 https://www.ophthalmologytimes.com/view/apellis-partners-launches-new-ga-won-t-wait-campaign-with-actor-henry-winkler 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/study-determines-retinal-vein-occlusion-after-covid-19-vaccinations-to-be-rare 2024-02-13 0.50 https://www.ophthalmologytimes.com/view/pearls-for-cataract-surgery-with-vance-thompson 2023-04-14 0.50 https://www.ophthalmologytimes.com/view/considering-retinal-detachments-and-predictors-of-poor-visual-outcomes-after-repair 2023-04-14 0.50 https://www.ophthalmologytimes.com/view/findings-from-the-persimmon-study-for-macula-off-retinal-detachments 2023-04-14 0.50 https://www.ophthalmologytimes.com/view/jennifer-lim-shares-research-on-vitrectomy-combined-with-kpro-surgery 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/early-real-world-study-concludes-brolucizumab-is-a-viable-alternative-for-select-patients-with-namd 2023-04-13 0.50 https://www.ophthalmologytimes.com/view/fda-grants-fast-track-designation-for-kpi-012-by-kala-pharmaceuticals 2023-04-13 0.50 https://www.ophthalmologytimes.com/view/3-key-pearls-for-pediatric-retinal-surgery- 2023-04-11 0.50 https://www.ophthalmologytimes.com/view/decreased-cone-densities-may-help-detect-and-monitor-multiple-sclerosis 2023-04-13 0.50 https://www.ophthalmologytimes.com/view/crystalline-lens-power-the-primary-driver-of-the-refractive-error-in-rop-eyes-treated-with-laser 2023-04-13 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-opportunities-to-enjoy-social-networking-events 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/arvo-2023-celebrating-the-beauty-of-diversity-in-science-and-nature 2023-04-18 0.50 https://www.ophthalmologytimes.com/view/why-an-altered-microbiome-can-be-associated-with-uveitis 2023-04-11 0.50 https://www.ophthalmologytimes.com/view/study-of-geographic-atrophy-to-better-understand-disease-progression-among-relatives 2023-04-10 0.50 https://www.ophthalmologytimes.com/view/gene-variants-point-to-a-potential-cause-of-age-related-macular-degeneration 2023-04-07 0.50 https://www.ophthalmologytimes.com/view/low-dose-atropine-drops-positive-impact-on-myopia-progression 2023-04-07 0.50 https://www.ophthalmologytimes.com/view/fda-grants-orphan-drug-designation-for-hg004-huidagene-s-gene-therapy-for-irds 2023-04-06 0.50 https://www.ophthalmologytimes.com/view/endogena-therapeutics-completes-dose-escalation-in-phase-1-2a-clinical-trial-of-ea-2353-for-treatment-of-retinitis-pigmentosa 2023-04-05 0.50 https://www.ophthalmologytimes.com/view/alimera-horus-pharma-expand-agreement-to-include-marketing-iluvien-in-the-nordic-countries 2023-04-03 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-reveals-positive-topline-results-from-restore-trial-of-mco-010-for-treatment-of-rp 2023-03-31 0.50 https://www.ophthalmologytimes.com/view/fda-approved-drug-demonstrates-potential-in-lab-models-for-blinding-childhood-disease 2023-03-31 0.50 https://www.ophthalmologytimes.com/view/new-form-of-omega-3-could-prevent-visual-decline-linked-with-alzheimer-s-disease 2023-03-31 0.50 https://www.ophthalmologytimes.com/view/possible-expansion-of-prior-authorization-to-medicare-fee-for-services-draws-objections-from-american-academy-of-ophthalmology 2023-03-30 0.50 https://www.ophthalmologytimes.com/view/retinal-scans-provide-a-non-invasive-inexpensive-method-to-track-aging 2023-03-29 0.50 https://www.ophthalmologytimes.com/view/samacare-partners-with-amerisourcebergen-to-offer-prior-authorization-platform-to-specialty-practices 2023-03-29 0.50 https://www.ophthalmologytimes.com/view/study-cones-in-retinal-degeneration-believed-to-be-dormant-may-retain-visual-function 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-1-2-clinical-trial-for-the-reatment-of-retinitis-pigmentosa-and-leber-congenital-amaurosis 2023-03-27 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-announces-results-from-phase-2-envision-study-of-ubx1325-in-patients-diagnosed-with-wet-amd 2023-03-27 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-debating-the-value-of-home-monitoring-as-a-management-option-for-amd 2023-03-23 0.50 https://www.ophthalmologytimes.com/view/abeona-therapeutics-announces-update-on-aav-ophthalmology-program 2023-03-25 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-weighing-the-merits-of-offering-teprotumumab-for-all-patients-with-thyroid-eye-disease 2023-03-23 0.50 https://www.ophthalmologytimes.com/view/researchers-find-eye-color-genes-are-key-for-retinal-health 2023-03-24 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-traveling-the-path-to-new-restorative-therapies 2023-03-21 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-importance-of-octa-in-clinical-practice 2023-03-21 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-durability-associated-with-multi-target-therapies-is-superior-to-anti-vegf-mono-target-therapy-in-amd 2023-03-21 0.50 https://www.ophthalmologytimes.com/view/researchers-study-frequency-of-retinopathy-in-patients-diagnosed-with-type-2-diabetes-mellitus 2023-03-23 0.50 https://www.ophthalmologytimes.com/view/study-focuses-on-link-between-retinoblastoma-and-maternal-smoking 2023-03-22 0.50 https://www.ophthalmologytimes.com/view/gene-editing-technique-reverses-vision-loss-in-mice 2023-03-20 0.50 https://www.ophthalmologytimes.com/view/suprachoroidal-ta-for-macular-edema-caused-by-noninfectious-uveitis 2023-03-14 0.50 https://www.ophthalmologytimes.com/view/early-detection-and-treatment-of-dr-and-dme-are-essential 2023-03-14 0.50 https://www.ophthalmologytimes.com/view/lumithera-reveals-sustained-vision-improvement-for-24-months-in-dry-amd-clinical-trial-data 2023-03-16 0.50 https://www.ophthalmologytimes.com/view/report-physician-payments-should-be-tied-to-inflation-based-index 2023-03-16 0.50 https://www.ophthalmologytimes.com/view/photoreceptor-viability-may-be-a-more-promising-target-than-ga-in-amd 2023-03-28 0.50 https://www.ophthalmologytimes.com/view/cophy-2023-sets-stage-for-evidence-based-debates-and-discussions 2023-03-15 0.50 https://www.ophthalmologytimes.com/view/poll-will-you-be-attending-cophy-in-lisbon-portugal-from-march-24-to-25- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/developments-in-gene-therapy-for-inherited-optic-neuropathies 2023-03-15 0.50 https://www.ophthalmologytimes.com/view/intergalactic-therapeutics-announces-positive-preclinical-results-of-its-non-viral-gene-therapy-platform-in-abca4-retinopathies 2023-03-15 0.50 https://www.ophthalmologytimes.com/view/vitrectomy-is-higher-speed-always-better- 2023-03-15 0.50 https://www.ophthalmologytimes.com/view/uf-health-researchers-gene-therapy-for-retina-disorder-shows-promise-in-early-testing 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/iol-designed-for-amd-offers-hope-for-patients 2023-03-14 0.50 https://www.ophthalmologytimes.com/view/international-keratoconus-academy-continues-to-provide-cutting-edge-education 2023-03-14 0.50 https://www.ophthalmologytimes.com/view/onl-therapeutics-gets-funding-to-move-lead-compound-into-phase-2-clinical-trial 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-offers-new-insights-into-rare-eye-disorders 2023-03-10 0.50 https://www.ophthalmologytimes.com/view/iveric-bio-releases-data-in-geographic-atrophy-from-avacincaptad-pegol-gather-trials 2023-03-10 0.50 https://www.ophthalmologytimes.com/view/anti-properdin-antibody-demonstrates-efficacy-in-a-primate-model-of-wet-amd-and-dry-amd 2023-03-10 0.50 https://www.ophthalmologytimes.com/view/study-outlines-new-way-to-prevent-common-causes-of-vision-loss 2023-03-05 0.50 https://www.ophthalmologytimes.com/view/new-insights-eye-damage-in-alzheimer-s-disease-patients 2023-03-05 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-announces-who-selection-of-sonpiretigene-isteparvovec-as-international-nonproprietary-name-for-mco-010 2023-03-01 0.50 https://www.ophthalmologytimes.com/view/praetego-awarded-300-000-by-national-eye-institute-to-advance-novel-oral-drug-for-diabetic-retinopathy 2023-03-01 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-photon-results-demonstrate-safety-efficacy-of-high-dose-aflibercept-for-treatment-of-dme 2023-02-28 0.50 https://www.ophthalmologytimes.com/view/ai-may-help-with-estimate-of-rp-progression 2023-02-27 0.50 https://www.ophthalmologytimes.com/view/researchers-study-anti-vegf-treatment-in-ocular-model-of-viral-infection 2023-02-27 0.50 https://www.ophthalmologytimes.com/view/apao-2023-testing-a-theory-for-children-with-keratoconus 2023-02-24 0.50 https://www.ophthalmologytimes.com/view/apao-2023-use-of-subthreshold-laser-for-dme 2023-02-22 0.50 https://www.ophthalmologytimes.com/view/apao-2023-beveled-tip-probe-added-to-arsenal-for-retinal-detachment-vitrectomy 2023-02-22 0.50 https://www.ophthalmologytimes.com/view/apao-2023-step-therapy-from-bevacizumab-to-aflibercept-for-dme 2023-02-21 0.50 https://www.ophthalmologytimes.com/view/apao-2023-diffuse-atrophy-in-children-key-to-development-of-pathologic-myopia-in-adults 2023-02-22 0.50 https://www.ophthalmologytimes.com/view/apao-2023-looking-at-anatomic-outcomes-in-matched-comparison-tenaya-and-lucerne-data 2023-02-21 0.50 https://www.ophthalmologytimes.com/view/apao-2023-retinoblastoma-in-2023 2023-02-21 0.50 https://www.ophthalmologytimes.com/view/dr-dme-ongoing-clinical-trials-and-new-diagnostic-tools 2023-02-20 0.50 https://www.ophthalmologytimes.com/view/reducing-treatment-burden-of-dr-dme 2023-02-20 0.50 https://www.ophthalmologytimes.com/view/fda-pegcetacoplan-approved-for-the-treatment-of-geographic-atrophy 2023-03-28 0.50 https://www.ophthalmologytimes.com/view/available-treatments-for-dr-dme 2023-02-06 0.50 https://www.ophthalmologytimes.com/view/fda-approves-nda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy 2023-03-28 0.50 https://www.ophthalmologytimes.com/view/case-3-faricimab-in-a-neovascular-namd-patient-with-persistent-fluid 2023-02-16 0.50 https://www.ophthalmologytimes.com/view/case-2-faricimab-in-treatment-na-ve-neovascular-namd-patient 2023-02-16 0.50 https://www.ophthalmologytimes.com/view/johns-hopkins-university-celanese-collaborating-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space 2023-02-16 0.50 https://www.ophthalmologytimes.com/view/akari-therapeutics-announces-development-progress-toward-ind-for-long-acting-pas-nomacopan-for-geographic-atrophy 2023-02-15 0.50 https://www.ophthalmologytimes.com/view/networking-and-social-activities-abound-for-apao-delegates 2023-02-13 0.50 https://www.ophthalmologytimes.com/view/brent-saunders-returning-to-bausch-lomb-as-ceo-board-chairman 2023-02-15 0.50 https://www.ophthalmologytimes.com/view/clinical-trial-underway-to-improve-vision-in-individuals-with-advanced-retinitis-pigmentosa 2023-02-15 0.50 https://www.ophthalmologytimes.com/view/case-1-faricimab-in-a-high-need-neovascular-namd-patient 2023-02-20 0.50 https://www.ophthalmologytimes.com/view/apao-fundraising-fun-get-in-gear 2023-02-13 0.50 https://www.ophthalmologytimes.com/view/shifting-medical-conference-paradigm-with-envision-summit-ophthalmology 2023-02-13 0.50 https://www.ophthalmologytimes.com/view/ocuphire-pharma-receives-fda-approval-of-nda-pdufa-date-set-for-mydriasis-treatment 2023-02-13 0.50 https://www.ophthalmologytimes.com/view/study-finds-early-anti-vegf-treatment-of-diabetic-retinopathy-does-not-improve-visual-acuity 2023-02-12 0.50 https://www.ophthalmologytimes.com/view/going-live-asia-pacific-academy-of-ophthalmology-offers-attendees-chance-to-reconnect-and-collaborate 2023-02-15 0.50 https://www.ophthalmologytimes.com/view/icymi-study-finds-americans-over-the-age-of-40-lack-sight-saving-knowledge-of-amd 2023-02-12 0.50 https://www.ophthalmologytimes.com/view/raising-awareness-generating-change-on-rare-eye-disease-day-for-300-million-people-worldwide-diagnosed-with-a-rare-disease 2023-02-08 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-data-from-derby-oaks-clinical-trials-for-geographic-atrophy 2023-02-08 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-characteristics-of-reactivations-responses-and-the-connection-between-them-as-seen-on-home-oct 2023-02-12 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-talon-phase-3b-study-results-brolucizumab-vs-aflibercept 2023-02-09 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-ellipsoid-zone-integrity-in-dry-amd 2023-02-08 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-the-tides-of-amd-reversed-with-drug-targeting-mitochondria-to-improve-photopic-vision 2023-02-09 0.50 https://www.ophthalmologytimes.com/view/the-mystery-of-geographic-atrophy-shifts-with-data 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/using-ophthalmic-artery-angioplasty-to-treat-amd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-comparing-ga-phenotypes-and-progression-rates-in-asians-non-asians 2023-03-28 0.50 https://www.ophthalmologytimes.com/view/stages-of-dr-dme-and-therapy-selection 2023-02-06 0.50 https://www.ophthalmologytimes.com/view/referring-patients-with-dr-dme-to-a-retina-specialist 2023-02-06 0.50 https://www.ophthalmologytimes.com/view/aflibercept-injection-approved-by-fda-to-treat-preterm-infants-diagnosed-with-rop 2023-02-09 0.50 https://www.ophthalmologytimes.com/view/genomic-risk-factors-for-amd-mapped-by-researchers 2023-02-07 0.50 https://www.ophthalmologytimes.com/view/close-study-outlines-updated-surgical-classification-for-the-treatment-of-large-full-thickness-macular-holes 2023-02-06 0.50 https://www.ophthalmologytimes.com/view/diagnostic-challenges-of-dr-dme 2023-02-03 0.50 https://www.ophthalmologytimes.com/view/multimodal-imaging-for-dr-dme 2023-02-03 0.50 https://www.ophthalmologytimes.com/view/4d-molecular-therapeutics-fda-clears-ind-application-for-4d-150-genetic-medicine-to-treat-dme 2023-02-03 0.50 https://www.ophthalmologytimes.com/view/hoya-vision-care-announces-3-year-partnership-with-orbis-international 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/fda-clears-ind-application-from-onl-therapeutics-for-onl1204-ophthalmic-solution 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/angiogenesis-2023-innovative-pharmacotherapies-in-spotlight 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-fda-gives-approval-to-ml6710i-laser-with-visudyne 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/cdc-investigating-infections-1-death-linked-to-eye-drops 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/poll-will-you-be-attending-the-2023-virtual-angiogenesis-exudation-and-degeneration-meeting 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyenuk-receives-approval-to-market-ai-screening-system-in-eu 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/study-examines-why-episodes-of-low-blood-sugar-worsen-eye-disease-in-people-with-diabetes 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/symptoms-of-dr-dme-and-recommendations 2023-01-30 0.50 https://www.ophthalmologytimes.com/view/prevalence-of-dr-dme-and-impact-of-early-diagnosis 2023-01-27 0.50 https://www.ophthalmologytimes.com/view/researchers-use-of-atropine-drops-after-glaucoma-surgery-may-impair-vision-extend-recovery 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/ocuphire-announces-topline-results-from-zeta-1-phase-2-trial-of-apx3330-in-diabetic-retinopathy 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-to-host-prph2-and-associated-retinal-diseases-workshop 2023-01-27 0.50 https://www.ophthalmologytimes.com/view/using-gene-therapy-to-target-usher-syndrome-type-2a 2023-01-25 0.50 https://www.ophthalmologytimes.com/view/retina-and-choroid-without-secrets 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/coherus-biosciences-acquiring-exclusive-us-commercial-rights-to-aflibercept-biosimilar 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/in-settlement-arizona-eye-surgery-network-to-pay-1-million-end-discriminatory-policies-towards-patients-with-disabilities 2023-01-20 0.50 https://www.ophthalmologytimes.com/view/study-links-obesity-to-macular-degeneration 2023-02-01 0.50 https://www.ophthalmologytimes.com/view/oregon-state-university-researchers-take-key-step-toward-new-treatment-for-hereditary-blindness 2023-01-18 0.50 https://www.ophthalmologytimes.com/view/study-black-and-hispanic-patients-treated-for-retinal-detachment-with-surgery-had-worse-vision-results-than-white-patients 2023-01-18 0.50 https://www.ophthalmologytimes.com/view/2023-top-5-predictions-for-ophthalmology-in-the-new-year 2023-01-17 0.50 https://www.ophthalmologytimes.com/view/study-more-than-a-quarter-of-older-americans-have-visual-impairment 2023-01-17 0.50 https://www.ophthalmologytimes.com/view/investigators-identify-connection-between-articles-published-before-ophthalmology-residency-future-career-path 2023-01-13 0.50 https://www.ophthalmologytimes.com/view/study-no-link-between-long-term-metformin-use-amd-risk 2023-01-13 0.50 https://www.ophthalmologytimes.com/view/icymi-investigators-find-lab-grown-retinal-eye-cells-make-key-connections-open-door-for-clinical-trials-to-treat-blindness 2023-01-13 0.50 https://www.ophthalmologytimes.com/view/thirona-spins-out-retina-business-to-pursue-long-term-growth-plans 2023-01-12 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-clinical-trial-for-gene-therapy-ft-001-for-treatment-of-leber-congenital-amaurosis-2 2023-01-06 0.50 https://www.ophthalmologytimes.com/view/retinal-degeneration-fund-invests-in-a-78m-series-b-for-perceive-biotherapeutics 2023-01-07 0.50 https://www.ophthalmologytimes.com/view/orion-1-biodegradable-dexamethasone-implant-sustained-visual-improvement-and-decreased-retinal-thickening-in-crvo-and-brvo 2023-01-05 0.50 https://www.ophthalmologytimes.com/view/study-targets-effect-of-dietary-nitrate-on-amd-progression 2023-01-05 0.50 https://www.ophthalmologytimes.com/view/everads-vivavision-partner-to-develop-therapies-for-retinal-diseases 2023-01-06 0.50 https://www.ophthalmologytimes.com/view/caroline-baumal-md-named-chief-medical-officer-of-apellis-pharmaceuticals 2023-01-05 0.50 https://www.ophthalmologytimes.com/view/study-google-searchers-may-underrepresent-ophthalmologists 2023-01-06 0.50 https://www.ophthalmologytimes.com/view/study-ids-signaling-cascade-behind-retina-regeneration-in-zebrafish 2022-12-27 0.50 https://www.ophthalmologytimes.com/view/nih-scientists-create-eye-tissue-using-3d-bioprinting 2023-01-01 0.50 https://www.ophthalmologytimes.com/view/heavy-silicone-oil-proves-effective-safe-for-persistent-full-thickness-macular-holes 2022-12-21 0.50 https://www.ophthalmologytimes.com/view/rop-researchers-offer-expanded-knowledge-about-development-progression 2022-12-20 0.50 https://www.ophthalmologytimes.com/view/2022-in-review-top-5-articles 2022-12-27 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-acquires-rights-to-pair-of-gene-therapy-product-candidates-for-inherited-retinal-diseases 2022-12-29 0.50 https://www.ophthalmologytimes.com/view/singapore-investigators-discover-novel-therapeutic-target-to-advance-treatment-of-diabetic-eye-diseases 2022-12-27 0.50 https://www.ophthalmologytimes.com/view/researchers-set-sights-on-finding-cure-for-age-related-macular-degeneration 2022-12-20 0.50 https://www.ophthalmologytimes.com/view/2022-in-review-orbis-international-ceo-look-back-offers-2023-outlook 2022-12-26 0.50 https://www.ophthalmologytimes.com/view/researchers-receive-grant-to-study-links-between-retinal-appearance-alzheimer-s 2022-12-20 0.50 https://www.ophthalmologytimes.com/view/university-at-buffalo-professor-recognized-for-retina-research 2022-12-19 0.50 https://www.ophthalmologytimes.com/view/researchers-fund-covid-impacts-depth-perception 2022-12-19 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd 2022-12-22 0.50 https://www.ophthalmologytimes.com/view/study-targets-signaling-cascade-behind-retina-regeneration-in-zebrafish 2022-12-15 0.50 https://www.ophthalmologytimes.com/view/congressional-budget-will-cut-medicare-reimbursement-for-physicians 2022-12-20 0.50 https://www.ophthalmologytimes.com/view/pixium-vision-completes-implantations-in-the-european-primavera-pivotal-trial-in-atrophic-dry-age-related-macular-degeneration 2022-12-19 0.50 https://www.ophthalmologytimes.com/view/collaboration-focusing-on-boosting-patient-access-participation-in-ophthalmology-clinical-trials 2022-12-19 0.50 https://www.ophthalmologytimes.com/view/rezolute-announces-initiation-of-a-phase-2-study-of-rz402-in-patients-with-diabetic-macular-edema 2022-12-18 0.50 https://www.ophthalmologytimes.com/view/long-term-efficacy-and-durability-of-latest-therapies-in-neovascular-amd-and-dmo 2023-01-25 0.50 https://www.ophthalmologytimes.com/view/the-pros-and-cons-of-local-resection-of-choroidal-melanoma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-retinal-cells-may-possess-ability-to-protect-themselves-from-diabetic-retinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oxurion-to-resume-kalahari-phase-2-part-b-study-in-diabetic-macular-edema-following-interim-analysis 2022-12-14 0.50 https://www.ophthalmologytimes.com/view/discussion-on-the-real-world-use-of-faricimab-with-dr-khanani-and-dr-khoramnia 2023-02-17 0.50 https://www.ophthalmologytimes.com/view/harrow-health-purchasing-u-s-rights-to-novartis-drugs 2022-12-14 0.50 https://www.ophthalmologytimes.com/view/2023-what-awaits-ophthalmology-in-the-year-ahead 2023-08-31 0.50 https://www.ophthalmologytimes.com/view/gene-therapy-offers-improved-retinal-sensitivity-visual-function-and-mobility 2022-12-08 0.50 https://www.ophthalmologytimes.com/view/ophthalmologist-discusses-impact-of-aging-on-patients-diagnosed-with-amd 2022-12-08 0.50 https://www.ophthalmologytimes.com/view/aviceda-clears-key-ind-toxicity-hurdle-with-positive-safety-profile-in-non-human-primates 2022-12-07 0.50 https://www.ophthalmologytimes.com/view/american-academy-of-ophthalmology-verana-health-roll-out-verana-research-network-an-iris-registry-initiative 2022-12-07 0.50 https://www.ophthalmologytimes.com/view/investigators-discover-new-potential-mechanism-for-vision-loss 2022-12-07 0.50 https://www.ophthalmologytimes.com/view/fda-grants-clearance-of-ind-application-to-opus-genetics-for-opgx-001-for-treatment-of-retinal-disease-lca5 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/fda-clears-ind-application-for-sparingvision-s-lead-asset-spvn06-for-treatment-of-retinitis-pigmentosa 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/one-of-two-widely-used-macular-degeneration-drugs-outperforming-other-at-weaning-patients-off-treatment-at-one-year-preliminary-study-shows 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/for-vegf-therapies-the-future-is-now 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/treating-amd-and-dme-with-faricimab-a-therapy-with-lower-treatment-burden 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/optogenetic-treatment-offers-hope-for-patients-with-end-stage-rp 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/retinai-launches-discovery-core-ai-powered-collaborative-platform-to-accelerate-clinical-and-academic-research-and-rwe-analysis-in-ophthalmology 2022-12-01 0.50 https://www.ophthalmologytimes.com/view/self-tonometry-provides-invaluable-insights-into-iop-fluctuations 2022-11-30 0.50 https://www.ophthalmologytimes.com/view/a-history-of-discovery-why-abbvie-focuses-on-challenging-eye-care-diseases 2022-11-28 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-declares-december-5-11-second-geographic-atrophy-awareness-week 2022-11-30 0.50 https://www.ophthalmologytimes.com/view/boosted-by-infusion-of-11-9-million-in-series-a-funding-re-vana-therapeutics-set-to-develop-ophthalmic-therapeutics 2022-11-30 0.50 https://www.ophthalmologytimes.com/view/biosimilars-what-clinicians-should-know-1 2023-02-13 0.50 https://www.ophthalmologytimes.com/view/pipeline-may-offer-options-for-combating-diabetic-eye-disease 2022-11-21 0.50 https://www.ophthalmologytimes.com/view/alcon-finalizes-deal-to-acquire-aerie-pharmaceuticals 2022-11-22 0.50 https://www.ophthalmologytimes.com/view/apellis-reveals-fda-acceptance-of-nda-amendment-and-new-pdufa-date-for-pegcetacoplan-for-ga 2022-11-18 0.50 https://www.ophthalmologytimes.com/view/belite-bio-completes-phase-3-clinical-trial-plans-for-lbs-008 2022-11-18 0.50 https://www.ophthalmologytimes.com/view/fda-approves-first-treatment-that-can-delay-onset-of-type-1-diabetes 2022-11-18 0.50 https://www.ophthalmologytimes.com/view/neolight-rolls-out-rop-risk-management-software-for-pediatric-ophthalmology 2022-11-17 0.50 https://www.ophthalmologytimes.com/view/leaders-in-academic-ophthalmology-discuss-ai-for-eye-screening 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/significance-of-periphery-in-diabetic-retinopathy-diagnosis-and-management 2022-11-15 0.50 https://www.ophthalmologytimes.com/view/managing-a-challenging-case-of-amd-and-dme 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opt-302-vegf-c-d-trap-molecule-for-amd-promising-in-phase-2b-moves-to-phase-3 2022-11-15 0.50 https://www.ophthalmologytimes.com/view/copd-the-eye-ocular-microstructures-affected-by-chronic-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/apellis-to-submit-24-month-phase-3-pegcetacoplan-data-to-fda-delays-pdufa-date 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/this-week-in-retina 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/rgx-314-earns-positive-interim-data-in-phase-2-altitude-trial-for-diabetic-retinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/timing-is-everything-with-early-treatment-of-amd 2022-11-02 0.50 https://www.ophthalmologytimes.com/view/nih-discovery-uncovers-essential-step-to-recharging-the-retina 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/sailing-study-and-extension-study-superiority-of-conbercept-over-laser-in-dme 2022-10-31 0.50 https://www.ophthalmologytimes.com/view/faricimab-svoa-improved-vision-in-patients-with-retinal-vein-occlusion-according-to-topline-phase-3-results 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/cataract-surgery-in-rp-patients-yield-marked-improvements-in-bcva 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/tenaya-lucerne-year-2-data-reveals-promising-results-for-faricimab 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aflibercept-earns-6-months-of-pediatric-market-exclusivity-from-fda 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-investigates-influence-of-telemedicine-on-pediatric-ophthalmic-visits 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opportunities-to-improve-patient-outcomes-revealed-by-interim-global-survey-analysis 2022-10-20 0.50 https://www.ophthalmologytimes.com/view/how-to-diagnose-geographic-atrophy-earlier 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/association-between-bmi-and-retinal-structural-changes-investigated 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ranibizumab-recall-genentech-recalls-ocular-implant-in-the-us 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retinal-nerve-fiber-layer-thinning-associated-with-the-degree-of-smoking-in-patients-with-poag 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/predicted-metastasis-free-survival-based-on-gene-expression-profiling-may-not-be-accurate 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/no-significant-association-found-between-anti-vegf-therapy-for-rop-and-pulmonary-hypertension 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-grants-fast-track-designation-to-nanoscope-therapeutics-for-mco-010-for-the-treatment-of-retinitis-pigmentosa 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/world-sight-day-donations-bring-vision-screening-corrective-lenses-to-impoverished-areas 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/world-sight-day-2022-eye-care-professionals-share-what-global-vision-means-to-them 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/visual-health-associated-with-depression-symptoms-altered-brain-neurobiology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/lost-to-followup-patients-with-amd-skip-sight-saving-treatment-experience-vision-loss 2022-10-11 0.50 https://www.ophthalmologytimes.com/view/intravitreal-steroid-injections-associated-with-a-higher-incidence-of-endophthalmitis-compared-with-other-intravitreal-injections 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/samsara-vision-update-concerto-trial-recruiting-patients-with-late-stage-amd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2022-recap-research-updates-innovations-on-the-horizon-presented-at-the-annual-meeting 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/risk-of-rhegmatogenous-retinal-detachment-rises-following-cataract-surgery 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/identifying-risk-factors-for-development-of-rhegmatogenous-retinal-detachments-in-fellow-eyes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fewer-ocular-symptoms-linked-to-e-cigarettes-than-traditional-cigarettes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/faricimab-for-namd-safe-effective-lower-treatment-burden-compared-with-aflibercept-in-pooled-tenaya-lucerne-phase-3-trials 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/health-care-restrictions-due-to-covid-19-had-no-negative-effects-on-status-of-dme 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/late-breaking-janssen-announces-data-from-2-gene-therapy-programs 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/acute-retinal-necrosis-retinal-detachment-rates-are-unaffected-by-early-treatment-with-intravitreal-antivirals-vitrectomy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/faricimab-eradicates-center-involved-dme-faster-than-aflibercept 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/understanding-fluid-dynamics-in-wet-macular-degeneration 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/iris-registry-comparing-dry-eye-disease-in-adult-and-pediatric-populations 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/continuous-range-of-motion-iol-scores-high-in-patient-satisfaction 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/pediatric-patients-have-higher-incidence-of-new-strabismus-following-tube-shunt-surgery-than-adult-patients 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/yosemite-rhine-treat-and-extend-data-show-favorable-results-for-faricimab-for-the-treatment-of-dme 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/poll-results-do-you-plan-to-attend-the-2022-aao-meeting- 2022-09-29 0.50 https://www.ophthalmologytimes.com/view/phase-3-sailing-study-intravitreal-conbercept-administered-as-needed-improves-vision-in-patients-with-dme 2022-09-27 0.50 https://www.ophthalmologytimes.com/view/abnormal-ophthalmic-findings-associated-with-young-patients-with-brain-tumors 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/high-resolution-multimodal-imaging-is-key-in-dry-amd-therapeutic-development-future-management 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-finds-ranibizumab-biosimilar-equivalent-in-safety-efficacy-for-the-treatment-of-wet-amd 2022-09-23 0.50 https://www.ophthalmologytimes.com/view/zika-virus-linked-with-fundus-lesions-in-newborns-in-french-territories 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/hydroxychloroquine-dosing-based-on-ophthalmology-guidelines-limits-sle-flares-may-cause-retinopathy-over-time 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/enrollment-completed-for-envision-phase-2-clinical-trial-investigating-ubx1325-for-the-treatment-of-amd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/increased-dosing-for-treatment-of-x-linked-retinoschisis-linked-with-inflammation-in-aav-rs1-trials 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/european-commission-approves-faricimab-for-treatment-of-wet-amd-dme 2022-09-19 0.50 https://www.ophthalmologytimes.com/view/suspension-of-amd-treatment-during-the-covid-19-pandemic-resulted-in-increased-rates-of-vision-loss 2022-09-16 0.50 https://www.ophthalmologytimes.com/view/poll-are-you-planning-to-attend-the-aao-2022-meeting- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/luna-first-patient-dosed-with-ixo-vec-in-phase-2-trial-for-treatment-of-wet-amd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/expanding-our-vision-of-steroid-eluting-implants 2022-09-19 0.50 https://www.ophthalmologytimes.com/view/aao-to-land-in-chicago-subspecialty-days-symposia-to-showcase-scientific-achievement 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/acing-the-suprachoroidal-injection-for-targeted-drug-delivery 2022-09-14 0.50 https://www.ophthalmologytimes.com/view/leveraging-artificial-intelligence-in-clinical-management-of-namd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/final-patient-completes-treatment-in-zeta-1-phase-2b-diabetic-retinopathy-clinical-trial 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/photon-pulsar-trials-aflibercept-meets-primary-endpoints-in-safety-efficacy 2022-09-08 0.50 https://www.ophthalmologytimes.com/view/first-patient-enrolled-in-phase-2-study-of-d-4517-2-for-treatment-of-wet-amd-dme 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/take-home-points-for-the-treatment-of-amd-and-dme 2022-09-28 0.50 https://www.ophthalmologytimes.com/view/unmet-needs-in-amd-and-dme 2022-09-28 0.50 https://www.ophthalmologytimes.com/view/incorporating-faricimab-in-clinical-practice 2022-09-28 0.50 https://www.ophthalmologytimes.com/view/moa-of-faricimab-and-2-year-data-review 2022-09-19 0.50 https://www.ophthalmologytimes.com/view/implications-of-treat-and-extend-with-faricimab-in-amd 2022-09-19 0.50 https://www.ophthalmologytimes.com/view/amd-and-dme-factors-affecting-treatment-selection-and-the-importance-of-shared-decision-making 2022-09-19 0.50 https://www.ophthalmologytimes.com/view/impact-of-amd-and-dme-on-quality-of-life 2022-09-20 0.50 https://www.ophthalmologytimes.com/view/first-us-patient-with-dry-amd-dosed-with-autologous-stem-cell-therapy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocs-01-improves-macular-thickness-visual-acuity-in-patients-with-dme-according-to-phase-2-data 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/novel-diagnostic-tool-for-uveitis-under-investigation 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/reviewing-insights-from-euretina-2022 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-declares-september-to-be-sports-eye-safety-month 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/what-are-you-most-excited-about-in-the-field-of-retina-tunde-peto-md-phd-weighs-in 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-soothing-effect-of-music-white-noise-for-babies-during-rop-examinations 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/light-study-first-analysis-of-gene-therapy-for-rpe65-inherited-retinal-dystrophies 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/visual-symptoms-after-covid-19-potential-for-retinal-manifestations 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/leveraging-noninvasive-ophthalmic-imaging-for-patients-with-alzheimer-disease-and-analyzing-uk-biobank-data 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/increased-risk-of-primary-angle-closure-glaucoma-linked-with-retinitis-pigmentosa 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phase-2-altitude-study-interim-data-analysis-rgx-314-provided-2-step-or-more-improvement-in-diabetic-severity 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/dealing-with-complications-of-silicone-oil 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/hair-cortisol-level-as-a-molecular-biomarker-in-retinitis-pigmentosa-patients 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2022-leadership-discusses-what-to-expect-outlines-women-in-retina-program 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/poll-results-will-you-be-attending-euretina-2022- 2022-08-30 0.50 https://www.ophthalmologytimes.com/view/novel-amd-gene-therapy-targets-mitochondrial-function-in-malfunctioning-cells 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/gene-therapy-partially-restores-cone-function-in-colorblind-children 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/investigating-possible-causes-of-myopia-in-schoolchildren-aged-3-14-years-in-tokyo 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/derby-oaks-24-month-data-shows-increased-effects-of-pegcetacoplan-in-patients-with-ga-over-time 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/achieving-high-definition-slit-lamp-imaging-via-smartphone-mirroring 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aerie-pharmaceuticals-acquired-by-alcon 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euroversion-case-contest-vitreoretinal-fellows-video-competition 2022-08-23 0.50 https://www.ophthalmologytimes.com/view/women-in-retina-raising-women-to-their-full-potential 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/apoe-gene-linked-to-alzheimer-disease-may-protect-retinal-ganglion-cells-study-finds 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-inflammation-linked-to-aav-gene-therapy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fight-retinal-blindness-registry-data-ranibizumab-and-aflibercept-safe-for-treating-dme-over-3-years 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retina-may-provide-clues-to-the-severity-of-multiple-sclerosis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/gene-associated-with-high-risk-of-alzheimer-disease-may-protect-against-glaucoma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/do-you-plan-to-attend-euretina-2022- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phase-1b-clinical-trial-begins-for-kio-301-for-vision-restoration-in-patients-with-retinitis-pigmentosa 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/sightlife-acquired-by-lions-eye-institute-for-transplant-and-research 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-approves-interchangeable-ranibizumab-biosimilar-from-coherus-biosciences 2022-08-12 0.50 https://www.ophthalmologytimes.com/view/euretina-2022-stepping-into-the-future-of-ophthalmology 2022-08-19 0.50 https://www.ophthalmologytimes.com/view/davio-trial-update-12-month-safety-results-indicate-no-serious-adverse-events-reduced-treatment-burden 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/impressions-and-takeaway-points-from-namd-patient-case-2 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/patient-case-2-81-year-old-male-with-namd 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/impressions-and-takeaway-points-from-dme-patient-case-1 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/patient-case-1-74-year-old-male-with-dme 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/phase-3-beacon-study-delivers-positive-topline-results-for-tarcocimab-in-patients-with-retinal-vein-occlusion 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phase-4-paladin-finds-fluocinolone-to-be-safe-effective-in-patients-with-diabetic-macular-edema 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/impressions-and-takeaway-points-from-patient-case-2 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/patient-case-2-73-year-old-female-with-namd 2022-08-18 0.50 https://www.ophthalmologytimes.com/view/impressions-and-takeaway-points-from-patient-case-1 2022-08-18 0.50